A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

NCT06449651 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Thrombocytopenia, Neonatal Alloimmune

Interventions

DRUG: Nipocalimab
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC